Table 2.

Smoking Abstinence Outcomes^a

Variable	Placebo	Treatment	P valueb
Week 12	n=42c	n=40
Prolonged abstinence	21 (50.0)	18 (45.0)	.65
Point prevalence abstinence	23 (54.8)	20 (50.0)	.67
Week 24	n=41d	n=39d
Prolonged abstinence	13 (49.1)	8 (20.5)	.26
Point prevalence abstinence	15 (36.6)	11 (28.2)	.42

^aData are presented as No. (percentage) unless indicated otherwise.

^bChi-square test.

^cTwo participants assigned to placebo were still receiving treatment when the study was terminated; lorcaserin was pulled from the market and the study had to be terminated; therefore, they were not included in this analysis.

^dThree participants assigned to placebo and 1 to treatment and were still receiving lorcaserin/placebo when the study was terminated; lorcaserin was pulled from the market and the study had to be terminated; therefore, they were not included in this analysis.